BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Vantive Transforms Vital Organ Therapies in Asia-Pacific

June 17, 2025 | Opinion | By Hithaishi C Bhaskar

With a 70-year legacy as Baxter's Kidney Care segment, Vantive, a global medtech leader in kidney care and acute therapies, reinforces its presence in Asia-Pacific with its manufacturing facility in Singapore



Chronic kidney disease (CKD) is a growing global health crisis that poses substantial clinical, economic and psychological burdens on patients and healthcare systems worldwide. Globally, an estimated 850 million people are affected by CKD and each year, a significant 4 million patients require dialysis treatment – a reality that warrants an urgent need for innovation in treatment.

Patients with CKD experience a progressive loss of renal function over time, often requiring dialysis or kidney transplantation for survival. Detecting and managing risk factors early are key to slowing its progression and improving outcomes for patients.

However, hospital-based dialysis and kidney transplantation are particularly high-cost treatments, making access limited in many regions, particularly in low and middle-income countries. Moreover, as the number of long-term care patients continue to increase, healthcare systems are facing mounting pressures, with many dialysis centers operating at or near-full capacity.

The advancement of medical diagnostic technologies, home-based dialysis and biomarker assessments play a vital role in diagnosing, monitoring and managing CKD, and enabling timely intervention to mitigate disease progression and enhance patient outcomes.

One such trailblazer is Vantive, a leader with a 70-year legacy in kidney care pioneering advanced vital organ therapies. Formerly the Kidney Care segment of **Baxter International Inc.**, Vantive has emerged as a new standalone vital organ therapy company in February 2025. With its mission to extend lives and expand possibilities, Vantive empowers patients

and healthcare professionals throughout therapy.

Steven Flynn, President for Asia-Pacific at Vantive, explains, “Our commitment is to support patients and care teams throughout therapy by optimising life-sustaining treatments that can be easily integrated into patients’ lives and providers’ practices. We aim to expand access to options that help break down barriers to starting and staying on therapy, and keep them more closely connected to their clinical teams.”

Driving a Comprehensive and Integrated Approach to Kidney Care:

With patients and care teams at the heart of its strategy, Vantive delivers innovative products, digitally-enhanced solutions and advanced services to support dialysis at home and in the clinic, as well as critical care therapy for kidney and other vital organs in an intensive care unit (ICU) setting.

“Transforming vital organ therapies begins with preserving patient freedom with home dialysis, expanding the potential of haemodialysis and extending our impact in acute therapies and multi-organ support. These priorities are underpinned by our renewed focus on patient and clinical experience through advanced services, as well as optimising care quality and efficiency with digital solutions”, explains Steven.

With innovative kidney care solutions that are flexible, collaborative, and accessible, Vantive leads the kidney care industry. Vantive’s technologies and solutions are designed to elevate the therapy experience, expand efficiencies for care teams, and enhance outcomes for patients.

Adulating Vantive's efforts to reduce kidney disease management burdens, Steven remarks, “In acute care, we are there to support clinicians with innovation that simplifies therapy administration and advances lifesaving critical care with novel diagnostic and therapeutic options for organ failure.”

Vantive supports over one million patient interactions daily across more than 100 countries, powered by a global workforce of nearly 23,000 specialists. The combination of global expertise, manufacturing footprint and a network of research and development hubs helps to ensure production of high-quality and cost-effective dialysis products.

“We consider ourselves a multi-domestic company, meaning we have key sites throughout the world to help us respond to local patient needs. This includes strategically positioning and investing in local operations like Singapore to meet the local patient needs whilst also supporting other markets as part of a global manufacturing network,” added Steven.

Empowering Patients and Clinicians with Advanced Digital Solutions for Augmented Care

Vantive offers a wide range of digital solutions that connect clinicians, enhance visibility and deliver timely insights throughout the patient’s treatment journey, enabling informed decisions and delivering the best care possible.

“In everything we do, we put the patient and their care team at the center of our strategy. In addition to helping patients stay more closely connected to their care teams, new analytics and clinical decision support tools can help clinicians more easily spot and act on important treatment trends,” said Steven.

Vantive's proprietary Sharesource Connectivity Platform is a two-way remote management platform that has supported over 60 million home dialysis therapy sessions globally, allowing patients to stay closely connected to their clinical team throughout treatment.

In home settings, Sharesource has been associated with reduced treatment dropouts and greater treatment adherence for PD patients. In addition, it is designed to empower clinicians with real-time remote access to patient treatment data, so that they can make the best decisions possible for their patients.

In intensive care settings, Vantive’s continuous renal replacement therapy from **PrisMax** has been delivering more favorable results for patients and simplifying therapy for clinicians in the ICU. The system simultaneously delivers therapies to manage acute kidney injury, sepsis and acute respiratory distress syndrome, and delivers treatment for autoimmune disorders.

The use of secure and innovative remote patient management technology not only supports clinical outcomes but helps to build more economically sustainable models of dialysis care around the world.

"Singapore has recently announced a goal of 30% PD uptake amongst new dialysis patients to address the increasing burden of CKD. We see Sharesource as an important option to support the Government's goal whilst empowering patients to continue to work and live a fulfilling life," concurs Steven spotlighting Vantive's commitment in APAC, particularly in Singapore as the prime biomedical hub in the region.

Charting Biomedical Market Expansion across Asia-Pacific:

In March 2025, Vantive unveiled its primary manufacturing hub in Asia-Pacific. Located in Woodlands, the facility currently produces more than 37 million units of PD solutions annually – supporting more than 4,000 direct and indirect local jobs and contributing more than SGD 450 million to Singapore's GDP. With over 30 years of local PD manufacturing history, the Woodlands facility serves as a major hub for patients in Singapore and beyond.

Just recently, Vantive's Woodlands manufacturing plant expanded its exports to now supply its PD solutions to Australia, New Zealand and the South Pacific.

"Designed with capacity to accommodate the growing demand for PD solutions and with continued investment in automation and operational excellence, our Woodlands plant is well positioned to scale and meet the needs of dialysis patients in the region. As we begin a new era in vital organ therapies and build on our legacy as a local manufacturer in Singapore, we want to continue to bring further innovation to this critical manufacturing hub that is proudly supporting Singapore patients, workers and the economy. We're extremely proud to support innovative medical manufacturing in Singapore and we'll continue to expand our investment in this critical manufacturing hub for the Asia-Pacific region." concludes **Steven Flynn**.

Spokesperson: Steven Flynn, President of Vantive Asia-Pacific interacted with Biospectrum Asia where he shared valuable insights on the company's transformation of vital organ therapies in Asia-Pacific. President Steven Flynn leads a cross-functional team that works to support the optimal delivery of kidney care and vital organ therapies across the APAC region. Previously, Flynn was senior vice president and president at Baxter International APAC. Over his 19 years with the company, he held positions of increasing responsibility, including as general manager for Australia and New Zealand. He began his career with key roles at TNT Logistics, now CEVA Logstics, and General Motors. Flynn previously served as vice chair for the Medical Technology Association of Australia (MTAA).

By Hithaishi Bhaskar